← All indications
Apnea
A transient absence of spontaneous respiration.
Subtype terms (1)
More specific conditions that are subtypes of Apnea in the MeSH hierarchy.
- Sleep Apnea Syndromes
89 drugs (76 approved, 13 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (7)
Phase 3 trials (3)
Phase 2 trials (4)
Phase 1 trials (2)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (51)
- Abbott
- Jazz Pharmaceuticals
- Cephalon
- Merck
- Wyeth
- GlaxoSmithKline
- Sunovion
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- United States Army
- Associação Fundo de Incentivo à Pesquisa
- Shahid Beheshti University of Medical Sciences
- University of Manitoba
- Chang Gung University
- Duke University
- Federal University of Rio Grande do Sul
- Institut National de la Santé Et de la Recherche Médicale, France
- Masih Daneshvari Hospital
- McGill University
- Skaraborg Hospital
- University of Lausanne
- University of Louisville
- University of Michigan
- University of South Florida
- University of Toronto
- University of Alberta
- University of Bologna
- University of Zurich
- Zagazig University
- +21 more
Organization Involved with Phase 3 Indications (31)
- Takeda
- Novo Nordisk
- Bioprojet
- Hamilton Health Sciences Corporation
- Nobel Pharmaceuticals
- University of Pennsylvania
- Case Western Reserve University
- Harvard University
- Harbin Medical University
- Kagawa University
- Mansoura University
- McMaster University
- Ohio State University
- Romaker & Associates
- University of Melbourne
- Chinese University of Hong Kong
- University of British Columbia
- University of Calgary
- University of Turku
- Papworth Hospital NHS Foundation Trust
- University of Limoges
- University of Alabama, Birmingham
- Children & Women's Health Centre of BC, Vancouver, Canada
- James Cook University Hospital, Middlesbrough, UK
- University of Western Ontario
- National Health and Medical Research Council, Australia
- Canadian Institutes of Health Research (CIHR)
- National Institute of Child Health and Human Development (NICHD)
- Government of France
- Fond de dotation AGIR pour les maladies chroniques
- +1 more
Organization Involved with Phase 2 Indications (33)
- Actelion
- Eisai
- Sanofi
- Vivus
- Bayer
- Solvay
- American Academy of Otolaryngology-Head and Neck Surgery Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Arizona
- American Heart Association
- Istituto Auxologico Italiano
- Johns Hopkins University
- Liaoyang Central Hospital
- Monash University
- Northwell Health
- Northwestern University
- University of Southern California
- Mayo Clinic
- Centre de Recherche en Nutrition Humaine Rhone-Alpe
- Mid-Atlantic Epilepsy and Sleep Center
- University of Texas at Houston
- State University of New York, Brooklyn
- University of Wisconsin
- University of Illinois at Chicago
- George Washington University
- Therapix Biosciences Ltd.
- Hektoen Institute for Medical Research
- Laboratoire Crinex
- Laboratoire Cidelec
- Bioikos Ambiente Srl
- +3 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (28)
- Hamad Medical Corporation
- Beijing Anzhen Hospital
- American SIDS Institute
- Advent Health
- Guangzhou Medical University
- Kyoto University
- Lund University
- Lovisenberg Diakonale Hospital
- Memorial Hermann Health System
- Rutgers University
- Stanford University
- Valley Health System
- University of Athens
- University of Bern
- Virginia Commonwealth University
- University of Virginia
- Yonsei University
- Capital Medical University
- Poznan University
- Tel Aviv University
- University of Montpellier
- Hebrew University
- University of Montreal
- University of Nice Sophia Antipolis
- Health Research Board, Ireland
- University of Antwerp
- People's Liberation Army of China
- National University of Ireland